Figure 15From: Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype Effects of dasatinib and/or Eto on the proportion of ALDH1-positive cells in breast cancer cells. The Aldefluor assay demonstrated that dasatinib alone and dasatinib with Eto increased the proportion of ALDH1-positive cells in BT-474 cells.Back to article page